[1]权修权,朴惠顺,康 琳,等.抗肿瘤靶向药物研究现状[J].中国药理学通报,2015,(05):610-614.
 QUAN Xiu-quan,PIAO Hui-shun,KANG Lin,et al.Research status of anti-tumor targted drugs[J].Chinese Pharmacological Bulletin,2015,(05):610-614.
点击复制

抗肿瘤靶向药物研究现状()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2015年05期
页码:
610-614
栏目:
讲座与综述
出版日期:
2015-05-15

文章信息/Info

Title:
Research status of anti-tumor targted drugs
作者:
权修权12朴惠顺2康 琳1尹学哲2高钟镐1
1.中国医学科学院药物研究所,天然药物活性物质与功能国家重点实验室,药物传输技术及 新型制剂北京市重点实验室,北京 100050; 2.延边大学附属医院,吉林 延吉 133000
Author(s):
QUAN Xiu-quan12PIAO Hui-shun2KANG Lin1YIN Xue-zhe2GAO Zhong-gao1
1.Chinese Academy of Medical Sciences,State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Drug Delivery Technology and New Formulations of the Key Laboratory of Beijing City,Beijing 100050,China; 2.Affiliated Hospital of Yanbian Universiy,Yanji Jilin 133000,China
关键词:
抗肿瘤 靶向治疗 药物 小分子 抗体 研究
Keywords:
anti-tumor targeted therapy drug small molecule antibody research
分类号:
R-05; R730.5; R979.1
文献标志码:
A
摘要:
目前针对恶性肿瘤的传统治疗药物已远远不能满足临床需要。近几年抗肿瘤靶向药物的研究取得了突破性的进展,给临床治疗带来了新的希望,它具有作用于特定靶点,直接抑制肿瘤细胞的生长,减少对正常细胞和组织器官的毒副作用,可以长期用药等优点。该文旨在近几年对小分子靶向药物和抗体靶向药物的最新研究作一综述。
Abstract:
Traditional treatments for malignant tumor are far from meeting the clinical demands. Recently, research on anti-tumor targeted drugs has made a significant breakthrough, which brings new hope for the treatment of malignant tumor. Anti-tumor targeted drugs can specifically target malignant tumor and directly inhibit the growth of tumor cells, showing no toxicity to the normal tissues and organs. Herein we reviewed the research progress of small molecular targeted drugs and antibody targeting new drugs.

参考文献/References:

[1] 王丽鸿. 分子靶向抗癌药物的研究进展[J].牡丹江医学院学报,2013,34(2):81-3. [1] Wang L H. The research progress of molecular targeted cancer drugs[J]. J Mudanjiang Med Univ, 2013,34(2):81-3.
[2] 王雅杰,王 宁.肿瘤分子靶向药物分类及作用机制[J]. 中国实用外科杂志,2013,30(77):526-8.
[2] Wang Y J,Wang N.Types of tumor molecular targeted therapies and mechanisms of action[J].Chin J Pract Surg, 2013,30(77):526-8.
[3] 孟 莹, 刘春水, 李 薇,等. 伊马替尼治疗慢性粒细胞性白血病患者的疗效分析[J]. 吉林大学学报(医学版),2012,38(3):563-6.
[3] Meng Y,Liu C S,Li W,et al.Efficacy analysis of imatinib in treatment of patients with chronic myeloid leukemia[J]. J Jilin Univ(Med Edi), 2012,38(3):563-6.
[4] 郑 军,范松青.靶向抗肿瘤小分子化合物类药物的研究[J]. 国际肿瘤学杂志,2012,39(3):172-5.
[4] Zheng J,Fan S Q. Advance of the targeted anti-tumor drugs with small molecule compounds[J]. J Int Oncol,2012,39(3):172-5.
[5] Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study[J]. J Thoracic Oncol,2012,7(9):1417-22.
[6] Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan study group 002 trial[J]. Oncologist,2012,17(6):863-70.
[7] Lee M, Siu R K, Ting K, et al. Effect of Nell-1 delivery on chondrocyte proliferationand cartilaginous extracellular matrix deposition[J]. Tissue Eng: Part A,2010,16(5):1791-800.
[8] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol,2010,11(2):121-8.
[9] Mok T S, D'arcangelo M, Califano R, et al. Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation[J]. Drugs,2012,72(1):3-10.
[10] Zhou C, Wu Y L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol,2011,12(8):735-42.
[11] 卢作勇, 陈 瑜. 尼洛替尼(Nilotinib)[J].中国制药信息,2012,28(7):25-6.
[11] Lu Z Y,Chen Y.Nilotinib[J].Chin Pharm Inform,2012,28(7):25-6.
[12] Kantarjian H M, Giles F J, Bhalla K N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results[J]. Blood,2011,117(4):1141-5.
[13] 余 萍, 柳 斌, 李 娟. 非小细胞肺癌分子靶向治疗的研究进展[J]. 肿瘤防治研究,2012,39(12):1507-13.
[13] Yu P,Liu B,Li J.Research progress of molecular targeted therapy for non-small cell lung cancer [J]. Cancer Res Prev Treatment,2012,39(12):1507-13.
[14] Lulla P D,Brammer J E,Bandeali S,et al.Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib[J].J Gastrointest Cancer,2013,44(1):98-101.
[15] Barone C,Basso M,Biolato M,et al.A phase Ⅱ study of sunitinib in advanced hepatocellular carcinoma[J].Dig Liver Dis,2013,45(8):692-8.
[16] Rosti G, Castagnetti F, Gugliotta G, et al. Dasatinib and nilotinib in imatinib-resistant philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison'[J]. Leuk Lymphoma,2010,51(4):583-91.
[17] Jagiello-Gruszfeld A,Tjulandin S,Dobrovolskaya N,et al.A sin-gle-arm phase Ⅱ trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer[J].Oncology,2010,79(1-2):129-35.
[18] Brave S R, Odedra R, James N H, et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer[J]. Int J Oncol,2011,39(1):271-8.
[19] CN S. Pazopanib in renal cell carcinoma[J]. Clin Adv Hematol Oncol,2010,8(4):232-3.
[20] Altorki N, Lane M E, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage Ⅰ/Ⅱ resectable non-small-cell lung cancer[J]. J Clin Oncol,2010,28(19):3131-7.
[21] 李梦君, 涂超, 贺洁宇,等. 凡德他尼治疗晚期非小细胞肺癌的Mete分析[J]. 肿瘤药学,2012,2(5):385-91.
[21] Li M J,Tu C,He J Y,et al.Vandetanib for advanced non-small cell lung cancer: a Meta-analysis[J]. Anti Tumor Pharm,2012,2(5):385-91.
[22] 张志强, 魏寅祥, 赵 青,等. 瓦他拉尼对乳腺癌耐药蛋白介导的肿瘤多药耐药的逆转研究[J]. 中国药理学通报,2014,30(6):774-82.
[22] Zhang Z Q,Wei Y X,Zhao Q,et al.Reversal effect of vatalanib on BCRP-mediated multidrug resistance[J].Chin Pharmacoll Bull,2014,30(6):774-82.
[23] 王尔兵. 治疗晚期肾癌的新靶向药物阿西替尼[J]. 肿瘤药学,2012,2(5):398-400.
[23]Wang E B.Treatment of advanced kidney cancer by new targeted drugs:Axitinib[J].Anti Tumor Pharm,2012,2(5):398-400.
[24] 邢爱敏. 抗肿瘤药Selumetinib[J]. 药学进展,2012,36(12):568-9.
[24] Xing A M. Anti-tumor drugs Selumetinib[J].Progr Pharm Sci,2012,36(12):568-9.
[25] 闫国婷, 胡军平, 张宇婷,等. 抗肿瘤靶向药物最新研究进展[J]. 煤炭与化工,2013,36(1):59-67.
[25] Yan G T,Hu J P,Zhang Y T,et al.Recent advance of the targeted anti-tumor drugs[J]. Coal Chem Ind,2013,36(1):59-67.
[26] 李文克, 李文倩, 冯建明. 多发性骨髓瘤治疗的研究进展[J]. 白血病淋巴瘤,2010,19(10):637-40.
[26] Li W K,Li W Q,Feng J M.Advances in the treatment of multiple myeloma[J]. J Leuk Lymphoma,2010,19(10):637-40.
[27] 孙园园, 潘 静. 硼替佐米联合VAD方案治疗初治多发性骨髓瘤的临床观察[J]. 中国药房,2011,22(10):903-5.
[27] Sun Y Y,Pan J. Clinical observation on Bortezomib and VAD regimens for multiple myeloma[J]. China Pharm,2011,22(10):903-5.
[28] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med,2007,356(22):2271-81.
[29] Zaytseva Y Y, Valentino J D, Gulhati P, et al. mTOR inhibitors in cancer therapy[J]. Cancer Lett,2012,319(1):1-7.
[30] 江文华, 解敏君, 唐小万,等. 利妥昔单抗治疗B细胞性非霍奇金淋巴瘤32例[J]. 中国药业,2013,22(11):87-8.
[30] Jiang W H,Xie M J,Tang X W,et al.Rituxan in treatment of B cell non-hodgkin's lymphoma in 32 cases[J].China Pharm,2013,22(11):87-8.
[31] Witzens-Harig M, Reiz M, Heiss C, et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial[J]. Ann Hematol,2009,88(1):51-7.
[32] 魏 涛, 龚忠义. 利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤疗效分析[J]. 河北医学,2014,20(1):108-10.
[32] Wei T,Gong Z Y.The efficacy of rituximab combined with CHOP for non-Hodgkin's lymphoma[J]. Hebei Med,2014,20(1):108-10.
[33] Bayoudh L, Afrit M, Daldoul O, et al. Trastuzumab(herceptin)for the medical treatment of breast cancer[J]. Tunis Med,2012,90(1):6-12.
[34] 陈志朋, 王德林. 肿瘤分子靶向治疗药物的临床应用研究进展[J]. 局解手术学杂志,2012,21(2):186-92.
[34] Chen Z P,Wang D L.Progress of clinical application of targeted therapic medicine for tumor molecule[J]. J Reg Anat Oper Surg,2012,21(2):186-92.
[35] Van Cutsem E,Kohne C H,Lang I,et al.Cetuximab plus irino-tecan,fluorouracil,and leucovorin as first-line treatment for me-tastatic colorectal cancer:updated analysis of overall survival ac-cording to tumor KRAS and BRAF mutation status[J].J Clin Oncol,2011,29(15):2011-9.
[36] 晁红雷, 韩晓东, 彭家远,等. 贝伐单抗联合化疗一线治疗转移性结直肠癌疗效的Meta分析[J]. 山东医药,2014,54(12):44-6.
[36] Chao H L,Han X D,Peng J Y,et al.Combination of Bevacizumab and MDT first-line for treatment of metastatic colorectal cancer: a Meta-analysis[J].Shandong Med J,2014,54(12):44-6.
[37] Peeters M, Cohn A, Kohne C H, et al. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma[J]. Clin Colorectal Cancer,2012,11(1):14-23.
[38] 郭 兵. 帕尼单抗联合化疗治疗晚期头颈部肿瘤的研究[J]. 临床和实验医学杂志,2013,12(22):1811-4.
[38] Guo B.Study on the efficacy of combined chemotherapy based on cisplatin and fluorouracil with or without panitumumab in treatment of advanced malignant tumor in head and neck[J]. J Clin Exper Med,2013,12(22):1811-4.

相似文献/References:

[1]施有琴,王荣,谢华,等.沙立度胺抗肿瘤作用机制与临床应用研究进展[J].中国药理学通报,2010,(08):0.
 SHI You qin,WANG Rong,XIE Hua,et al.Progress in the research of antitumor mechanism and clinical application of thalidomide[J].Chinese Pharmacological Bulletin,2010,(05):0.
[2]张冬青,汪德清,李卉,等.黄芪总黄酮对K562细胞凋亡及细胞周期的影响[J].中国药理学通报,2010,(01):136.
 ZHANG Dong qing,WANG De qing,LI Hui,et al.Effect of total flavonoids of astragalus on growth inhibition and apoptosis induction in human erythroleukemia cell line K562[J].Chinese Pharmacological Bulletin,2010,(05):136.
[3]抑制作用及其机制刘浩,蒋志文,童旭辉,等.硫酸乙酰肝素蛋白聚糖对C3H小鼠乳腺癌移植瘤的[J].中国药理学通报,2008,(06):0.
 LIU Hao,JIANG Zhi wen,TONG Xu hui,et al.Inhibitory effects of heparan sulfate proteoglycan on transplanted breast cancer in C3H mice[J].Chinese Pharmacological Bulletin,2008,(05):0.
[4]韩华,易杨华,喇明平,等.糙海参皂苷Scabraside A、B的抗真菌和抗肿瘤活性[J].中国药理学通报,2008,(08):0.
 HAN Hua,YI Yang hua,LA Ming ping,et al.Studies on antifungal and antitumor activities of scabraside A、B from Holothuria scabra Jaeger[J].Chinese Pharmacological Bulletin,2008,(05):0.
[5]王辉,雷志勇,陈虹,等.土槿乙酸衍生物PBLY体外抗肿瘤作用及其机制研究[J].中国药理学通报,2008,(09):0.
 WANG Hui,LEI Zhi yong,CHEN hong,et al.Antitumor activity of PBLY and its mechanism in vitro[J].Chinese Pharmacological Bulletin,2008,(05):0.
[6]史大永,许凤,贺娟,等.小粘膜藻不同提取部位体外抗肿瘤作用研究[J].中国药理学通报,2008,(10):0.
 SHI Da yong,XU Feng,HE Juan,et al.Study on the antitumor effect of different solution extracts from the brown alga Leathesia nana[J].Chinese Pharmacological Bulletin,2008,(05):0.
[7]李璘,邱蓉丽,程革,等.女贞子多糖抗肿瘤作用研究[J].中国药理学通报,2008,(12):0.
 LI Lin,QIU Rong li,CHENG Ge,et al.The study on the antitumor effect of LLP in vitro and in vivo[J].Chinese Pharmacological Bulletin,2008,(05):0.
[8]沈杰,张冬梅,徐力致,等.一种新型低毒的有机铜化合物的合成、鉴定及抗肿瘤活性研究[J].中国药理学通报,2009,(01):0.
 SHEN Jie,ZHANG Dong mei,XU Li zhi,et al.A study on the synthesis, identification and antitumor properties of a novel low toxic organic copper complex[J].Chinese Pharmacological Bulletin,2009,(05):0.
[9]叶红,余为一.药用真菌葡聚糖免疫调节作用的研究进展[J].中国药理学通报,2009,(02):0.
 YE Hong,YU Wei yi.Progress on the study of the immunomodulating action of glucans from macrofungi[J].Chinese Pharmacological Bulletin,2009,(05):0.
[10]张艳春,周金培,吴晓明.血管紧张素Ⅱ及其受体在肿瘤中作用的研究进展[J].中国药理学通报,2009,(04):0.
 ZHANG Yan chun,ZHOU Jin pei,WU Xiao ming.Research progress on the function of angiotensin Ⅱ receptors in tumor[J].Chinese Pharmacological Bulletin,2009,(05):0.

备注/Memo

备注/Memo:
收稿日期:2015-02-25,修回日期:2015-03-24 基金项目:国家自然科学基金资助项目(No 81373342); 北京市自然科学基金资助项目(No 2141004,7142114) 作者简介:权修权(1978-),男,博士,主治医师,研究方向:肺癌靶向治疗,E-mail:xiuquan0517@163.com; 高钟镐(1964-),男,博士,教授,博士生导师,研究方向:肿瘤靶向制剂的研究,通讯作者,E-mail:zggao@imm.ac.cn
更新日期/Last Update: 1900-01-01